Bank of Hawaii’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$791K Sell
1,024
-25
-2% -$19.1K 0.04% 149
2025
Q4
$810K Buy
1,049
+26
+3% +$17.7K 0.04% 156
2025
Q3
$575K Buy
1,023
+276
+37% +$156K 0.03% 176
2025
Q2
$392K Buy
+747
New +$417K 0.02% 203
2020
Q4
Sell
-361
Closed -$202K 270
2020
Q3
$202K Sell
361
-150
-29% -$91K 0.01% 246
2020
Q2
$319K Sell
511
-676
-57% -$384K 0.02% 234
2020
Q1
$580K Buy
+1,187
New +$490K 0.05% 185
2019
Q2
Sell
-1,383
Closed -$568K 337
2019
Q1
$568K Buy
1,383
+278
+25% +$114K 0.04% 223
2018
Q4
$413K Sell
1,105
-953
-46% -$349K 0.04% 253
2018
Q3
$832K Buy
2,058
+333
+19% +$127K 0.06% 190
2018
Q2
$595K Buy
1,725
+205
+13% +$64.1K 0.05% 217
2018
Q1
$523K Buy
+1,520
New +$529K 0.04% 230

Other funds holding REGN

Bank of Hawaii's REGN Position: Q1 2026 in Review

Bank of Hawaii reduced its Regeneron Pharmaceuticals (REGN) stake by 2.4% in Q1 2026, selling an estimated $19.1K and leaving 1,024 shares worth $791K. The position accounts for 0.04% of the portfolio, ranked #149.

Bank of Hawaii first reported a position in REGN in Q1 2018 and has held it in 12 quarters since. The position peaked at $832K in Q3 2018. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Bank of Hawaii held 1,024 shares of Regeneron Pharmaceuticals worth $791K as of Q1 2026.
  • Bank of Hawaii sold 25 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $19.1K.
  • Regeneron Pharmaceuticals made up 0.04% of Bank of Hawaii's portfolio in Q1 2026, its #149 holding.
  • Bank of Hawaii first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 12 quarters since.
  • Bank of Hawaii's Regeneron Pharmaceuticals position peaked at $832K in Q3 2018.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Bank of Hawaii's 13F filing for Q1 2026, filed 15 May 2026.